Skip to main content

Table 1 Average Score and Number of Cystadenomas per Kidney for A/J and C57BL/6 Tsc2+/- Cohorts

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

Tsc2+/-Cohort
(strain, treatment, age)
Score per Kidney
(ave ± std dev)
Number per Kidney
(ave ± std dev)
% Reduction in Score per Kidney vs. Group 4 n Group Number Number of Rapa Doses Duration of Treatment Total Dose per Mouse
(mg)
C57BL/6, untreated, 12 months 15.19 ± 9.39 5.94 ± 2.79   8     
A/J, untreated, 3 months 6.50 ± 4.60 4.00 ± 1.69   4     
A/J, untreated, 5 months 33.00 ± 13.53 13.00 ± 4.28   4     
A/J, untreated, 7 months 57.75 ± 18.24 22.50 ± 5.88   4     
A/J, untreated, 9 months 74.47 ± 23.07 22.63 ± 6.66   16     
**A/J, untreated, 12 months 120.20 ± 52.53 35.25 ± 14.22   8 4    
Group 1
*A/J rapa daily × 4 weeks then weekly × 8 weeks
21.50 ± 8.38 7.38 ± 2.83 82% 8 1 28 12 weeks 6.72
Group 2
*A/J rapa daily × 4 weeks
41.13 ± 25.33 13.25 ± 6.32 66% 8 2 20 4 weeks 4.8
Group 3
*A/J rapa weekly × 12 weeks
22.61 ± 9.89 8.17 ± 3.07 81% 9 3 12 12 weeks 2.88
  1. * All treatments started at 9 months of age, and mice were euthanized 12 weeks later (at ~12 months of age)
  2. ** Untreated controls were euthanized at 12 months of age